Irinotecan dosing – UGT1A1

Irinotecan is an anti-cancer agent that is used for the treatment of metastatic carcinoma of the colon or rectum. Although it prolongs survival, it causes severe (grade 3-4) diarrhea and neutropenia in approximately 20-35% of patients treated.  The ability to predict patients who will eventually suffer these potentially fatal toxicities is an important consideration when using irinotecan.

Irinotecan is converted in the liver to its active metabolite, SN-38, which subsequently gets conjugated to its glucuronide, SN-38G that is excreted from the body.  UGT1A1 is involved in the glucuronidation of SN-38 to its glucuronide.  Decreased levels of glucuronidation results in elevated amounts of SN-38 that is responsible for the severe diarrhea and neutropenia phenotypes in patients. Individuals homozygous for the A(TA)7TAA allele of UGT1A1 gene are at an elevated risk of developing toxicity phenotypes with irinotecan treatment.

Detection:  We offer DNA test for the detection of A(TA)7TAA promotor polymorphism of UGT1A1 gene specific for the Caucasian population using the PCR-amplification technique and sizing by polyacrylamide gel-electrophoresis.

Specimen Requirements:  genomic DNA is isolated from the peripheral blood, collected in 2 ml EDTA Vacutainer tube (lavender top). In case if DNA is already extracted, the minimum concentration should be 25 ng/µl.

Transportation: The blood specimen can be stored in the refrigerator (for 1 or 2 days) and shipped to CMG at room temperature. In case of the DNA, it can be shipped to CMG at room temperature within 1-2 days.

Turnaround time: 10-15 days

For further information please contact:
Tel.: (+374 10) 544367
Fax: (+374 10) 544366

Գին՝ 15 000 AMD